Editas Medicine, Inc. — Form 10-Q
Filed August 5, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 3/100
What the filing says
CEO Gilmore O'Neill and CFO Amy Parison certified the Q2 2026 10-Q (period ended June 30, 2026) on August 5, 2026, affirming the absence of material misstatements, fair presentation of financial statements, and effectiveness of disclosure controls and internal controls over financial reporting. No specific financial results, transactions, or operational developments are disclosed in these certification exhibits.
Why this rating
Boilerplate SOX certification exhibits; routine periodic disclosure with no substance about business performance, transactions, or material changes relative to $191M market cap.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.